Ennapadam Venkatraman

17.1k total citations · 6 hit papers
116 papers, 13.2k citations indexed

About

Ennapadam Venkatraman is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Ennapadam Venkatraman has authored 116 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pulmonary and Respiratory Medicine, 36 papers in Surgery and 28 papers in Oncology. Recurrent topics in Ennapadam Venkatraman's work include Ovarian cancer diagnosis and treatment (23 papers), Advanced Radiotherapy Techniques (20 papers) and Prostate Cancer Diagnosis and Treatment (18 papers). Ennapadam Venkatraman is often cited by papers focused on Ovarian cancer diagnosis and treatment (23 papers), Advanced Radiotherapy Techniques (20 papers) and Prostate Cancer Diagnosis and Treatment (18 papers). Ennapadam Venkatraman collaborates with scholars based in United States, Germany and Cyprus. Ennapadam Venkatraman's co-authors include Valerie W. Rusch, Michael J. Zeléfsky, Zvi Fuks, Steven A. Leibel, Richard R. Barakat, Mark G. Kris, Manjit S. Bains, Margie Hunt, Robert J. Downey and Vincent A. Miller and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Ennapadam Venkatraman

116 papers receiving 12.8k citations

Hit Papers

Bronchioloalveolar Pathologic Subtype and Smoking History... 2001 2026 2009 2017 2004 2006 2002 2001 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
    2004 628 citations Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology profile →
  2. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
    2006 623 citations DuyKhanh Pham, Naiyer A. Rizvi et al. Clinical Cancer Research profile →
  3. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients
    2002 613 citations Michael J. Zeléfsky, Ennapadam Venkatraman et al. International Journal of Radiation Oncology*Biology*Physics profile →
  4. HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER
    2001 553 citations Michael J. Zeléfsky, Ennapadam Venkatraman et al. profile →
  5. Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
    2002 498 citations Martee L. Hensley, Ennapadam Venkatraman et al. Journal of Clinical Oncology profile →
  6. High-Dose, Single-Fraction Image-Guided Intensity-Modulated Radiotherapy for Metastatic Spinal Lesions
    2008 389 citations Ennapadam Venkatraman, Michael J. Zeléfsky et al. International Journal of Radiation Oncology*Biology*Physics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ennapadam Venkatraman United States 62 8.1k 3.6k 3.3k 2.6k 2.0k 116 13.2k
William T. Sause United States 50 8.3k 1.0× 2.3k 0.6× 4.7k 1.4× 2.3k 0.9× 1.8k 0.9× 173 12.3k
Gerald E. Hanks United States 76 13.9k 1.7× 3.9k 1.1× 2.2k 0.7× 6.6k 2.5× 3.3k 1.6× 393 19.4k
Wim L.J. van Putten Netherlands 56 2.8k 0.3× 1.5k 0.4× 2.6k 0.8× 1.5k 0.6× 1.0k 0.5× 155 10.5k
Perry W. Grigsby United States 61 2.0k 0.2× 3.2k 0.9× 1.4k 0.4× 1.2k 0.4× 3.5k 1.7× 250 11.1k
Sushil Beriwal United States 40 1.7k 0.2× 2.7k 0.8× 2.0k 0.6× 1.6k 0.6× 1.4k 0.7× 405 8.2k
Richard Pötter Austria 70 4.8k 0.6× 8.1k 2.3× 2.4k 0.7× 6.7k 2.6× 4.6k 2.3× 468 19.6k
Anthony Fyles Canada 56 1.7k 0.2× 2.6k 0.7× 2.8k 0.8× 2.0k 0.8× 2.7k 1.3× 270 12.1k
Simon S. Lo United States 47 4.6k 0.6× 3.1k 0.9× 2.2k 0.7× 2.2k 0.9× 2.2k 1.1× 356 9.4k
A.G. Morganti Italy 38 2.8k 0.3× 2.6k 0.7× 2.9k 0.9× 1.4k 0.5× 2.0k 1.0× 438 7.3k
Alvaro A. Martinez United States 75 9.3k 1.1× 2.8k 0.8× 1.9k 0.6× 9.9k 3.8× 5.4k 2.7× 393 17.2k

Countries citing papers authored by Ennapadam Venkatraman

Since Specialization
Citations

This map shows the geographic impact of Ennapadam Venkatraman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ennapadam Venkatraman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ennapadam Venkatraman more than expected).

Fields of papers citing papers by Ennapadam Venkatraman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ennapadam Venkatraman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ennapadam Venkatraman. The network helps show where Ennapadam Venkatraman may publish in the future.

Co-authorship network of co-authors of Ennapadam Venkatraman

This figure shows the co-authorship network connecting the top 25 collaborators of Ennapadam Venkatraman. A scholar is included among the top collaborators of Ennapadam Venkatraman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ennapadam Venkatraman. Ennapadam Venkatraman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Azzoli, Christopher G., Lee M. Krug, Vincent A. Miller, et al.. (2007). A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(7). 638–644. 11 indexed citations
2.
Flores, Raja M., Maureen F. Zakowski, Ennapadam Venkatraman, et al.. (2007). Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center. Journal of Thoracic Oncology. 2(10). 957–965. 177 indexed citations
3.
Lee, Nancy Y., Kelvin Chan, Justin E. Bekelman, et al.. (2007). Salvage Re-Irradiation for Recurrent Head and Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 68(3). 731–740. 198 indexed citations
4.
Azzoli, Christopher G., Lee M. Krug, Jorge Gómez, et al.. (2007). A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors. Clinical Cancer Research. 13(9). 2692–2698. 25 indexed citations
5.
6.
Lee, Nancy Y., Fernando Freire de Arruda, Dev R. Puri, et al.. (2006). A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. International Journal of Radiation Oncology*Biology*Physics. 66(4). 966–974. 125 indexed citations
7.
Stover, Diane E., et al.. (2006). Prevalence of COPD in Women Compared to Men Around the Time of Diagnosis of Primary Lung Cancer. CHEST Journal. 129(5). 1305–1312. 160 indexed citations
8.
Flores, Raja M., Lee M. Krug, Kenneth E. Rosenzweig, et al.. (2006). Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial. Journal of Thoracic Oncology. 1(4). 289–295. 115 indexed citations
9.
Leitão, Mario M., Jeff Boyd, Amanda Hummer, et al.. (2004). Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma. The American Journal of Surgical Pathology. 28(2). 147–159. 50 indexed citations
10.
Sarkaria, Inderpal S., DuyKhanh Pham, Ronald Ghossein, et al.. (2004). SCCRO Expression Correlates With Invasive Progression in Bronchioloalveolar Carcinoma. The Annals of Thoracic Surgery. 78(5). 1734–1741. 16 indexed citations
11.
Leitão, Mario M., Amanda Hummer, Don S. Dizon, et al.. (2003). Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecologic Oncology. 91(1). 123–129. 36 indexed citations
12.
Patel, Jyoti D., Mark G. Kris, Ennapadam Venkatraman, et al.. (2003). O-207 Collateral damage from the lung cancer explosion in American women: Has sex migration replaced stage migration as a confounding factor in lung cancer trials?. Lung Cancer. 41. S61–S61. 4 indexed citations
13.
Alektiar, Kaled M., Andrea B. McKee, Oscar Lin, et al.. (2002). The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma. Cancer. 95(2). 316–321. 19 indexed citations
14.
Barakat, Richard R., Paul Sabbatini, Margarita V. Revzin, et al.. (2002). Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up. Journal of Clinical Oncology. 20(3). 694–698. 49 indexed citations
15.
Dennis, S., John B. Liao, Larry Léon, et al.. (2001). Identification of Prognostic Factors in Advanced Epithelial Ovarian Carcinoma. Gynecologic Oncology. 82(3). 532–537. 201 indexed citations
16.
Gemignani, Mary L., Kaled M. Alektiar, Mario M. Leitão, et al.. (2001). Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. International Journal of Radiation Oncology*Biology*Physics. 50(3). 687–694. 61 indexed citations
17.
Jackson, Andrew, Michael J. Zeléfsky, Daniel F. Cowan, et al.. (1998). Rectal bleeding after conformal radiotherapy of prostate cancer and dose volume histograms. International Journal of Radiation Oncology*Biology*Physics. 42(1). 217–217. 8 indexed citations
18.
Abu‐Rustum, Nadeem R., Richard R. Barakat, Ennapadam Venkatraman, & David R. Spriggs. (1997). Chemotherapy and Total Parenteral Nutrition for Advanced Ovarian Cancer with Bowel Obstruction. Gynecologic Oncology. 64(3). 493–495. 52 indexed citations
19.
Curtin, John P., William J. Hoskins, Ennapadam Venkatraman, et al.. (1996). Adjuvant Chemotherapy versus Chemotherapy plus Pelvic Irradiation for High-Risk Cervical Cancer Patients after Radical Hysterectomy and Pelvic Lymphadenectomy (RH-PLND): A Randomized Phase III Trial. Gynecologic Oncology. 61(1). 3–10. 71 indexed citations
20.
Miller, Vincent A., James R. Rigas, Prudence A. Francis, et al.. (1995). Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer. 75(4). 968–972. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William T. Sause Breakdown of academic impact, for papers by Gerald E. Hanks Breakdown of academic impact, for papers by Wim L.J. van Putten Breakdown of academic impact, for papers by Perry W. Grigsby Breakdown of academic impact, for papers by Sushil Beriwal Breakdown of academic impact, for papers by Richard Pötter Breakdown of academic impact, for papers by Anthony Fyles Breakdown of academic impact, for papers by Simon S. Lo Breakdown of academic impact, for papers by A.G. Morganti Breakdown of academic impact, for papers by Alvaro A. Martinez
Rankless by CCL
2026